Rob RooversSenior Director, Preclinical Development at LAVA Therapeutics
A (bio-)chemist by training, I did a PhD in antibody phage display, antibody engineering and the development of human(ized) antibodies for therapeutic and diagnostic oncology applications. After a post-doc in academia, I started collaborating (from within the university) with Biotech companies for the development of therapeutic antibodies in oncology. After a couple of years, I joined the early ranks of Merus and co-developed several bispecifics that are now being tested in phase 1 and 2 trials, before I entered LAVA Therapeutics as one of the first employees. My current responsibility as head of preclinical development encompasses the development of the pipeline of LAVA, from panel generation to the writing of the IB to support CTA/IND.